Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Optimapharm Nordic Oy
OY
Active
Y-tunnus 1982804-3
Tekniikantie 12, 02150
Espoo
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2005 · 20 years old
30 employees
www.crowncro.fi
Share
Finland
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Optimapharm Nordic Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
0M
3M
6M
9M
13M
10M
2019
6M
2020
11M
2021
9M
2022
6M
2024
EBITDA
EUR millions
1M
0M
-1M
-3M
-4M
1M
2019
-3M
-400%
2020
0M
+100%
2021
0M
0%
2022
1M
+100%
2024
Income statement
EUR thousands
Item
2019
2020
2021
2022
2024
Revenue
10 391
6 454
10 698
9 148
6 486
Staff expenses
−4 558
−4 416
−3 934
−3 919
−2 670
EBITDA
1 253
−3 046
39
−89
1 105
Depreciation & amort.
−203
−150
−97
−94
−281
EBIT
1 050
−3 197
−57
−183
824
Net financials
−220
−253
−194
−56
−0
Profit before tax
830
−3 450
−252
−239
823
Tax
−0
−0
−0
−0
−0
Net profit
830
−3 450
−252
−239
823
Balance sheet
EUR thousands
Item
2019
2020
2021
2022
2024
Total assets
5 704
2 725
3 308
3 198
2 525
Equity
674
−3 293
−2 085
−2 324
−385
Long-term debt
825
1 320
1 996
1 996
0
Short-term debt
4 205
4 698
3 398
3 527
2 910
Total debt
5 030
6 018
5 394
5 523
2 910
Financial ratios
5-year trend
EBITDA margin
17.0%
This company
15.8%
Market median
+8% vs market
2019
2024
Equity ratio
-15.2%
This company
38.2%
Market median
-140% vs market
2019
2024
Return on equity
82342600.0%
This company
18.4%
Market median
+447514030% vs market
2019
2024
Net profit margin
12.7%
This company
8.1%
Market median
+57% vs market
2019
2024
Asset turnover
2.57×
This company
1.12×
Market median
+129% vs market
2019
2024
Debt / equity
7.56×
This company
0.62×
Market median
-1119% vs market
2019
2024
Annual reports & filings
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
View
PDF
More on Optimapharm Nordic Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
